The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...